findmyKOL
Clinical trialNCT05377905RecruitingPhase 1/PHASE2Interventional

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

SponsorFalo, Louis, MDEnrollment48Cutaneous Squamous Cell CarcinomaSkin Cancers - Squamous Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemotherapy agent. The overall goal of this study is to test the safety and effectiveness of these patches. The investigators have established the highest tolerated dose at 50 micrograms in a previous study for a different type of cancer that affects the skin. The investigators will thoroughly evaluate the skin where the patches are applied.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

    Jason Luke, MDLouis D Falo, MD, PhDMelissa M Pugliano-Mauro, MDNicolena Verardi, PA-COleg E Akilov, MD, PhDTimothy Patton, DO
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Microneedle Array Doxorubicin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Sept 2023
Primary completion
31 Mar 2027
Completion
31 Dec 2027
Last update posted
9 Apr 2026
Registered enrollment
48
Registry id
NCT05377905
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.